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Abstract
Introduction: The aim of the present study was to investigate the changes in serum progranulin and sex hormone levels in infertile 
women with obesity. 
Material and methods: A total of 171 infertile women who had fertility desire were included in this cross-sectional study. The initial 
assessment included measurements of weight, height, waist circumference, and hip circumference to calculate body mass index (BMI) 
and waist/hip ratio. All participants were categorised into two groups in accordance with BMI as a control group (< 30 kg/m2, n = 135) 
and a study group (≥ 30 kg/m2, n = 36). After anthropometric measurements, venous blood samples were taken for analyses of oestradiol 
and follicle stimulating hormone (FSH), luteinising hormone, total testosterone (TT), 17-hydroxyprogesterone, dehydroepiandrosterone 
sulphate, anti-Müllerian hormone, and progranulin.
Results: The present study demonstrated that the overweight women had higher FSH levels (p < 0.01). Elevated TT levels were detected 
in obese women (p < 0.05). Progranulin concentrations were higher in the study group than in the control group (p < 0.05). Regression 
analysis demonstrated that there was a relationship between the serum progranulin concentrations and BMI (p < 0.05). 
Conclusions: Our findings support that the elevated progranulin levels are associated with obesity in infertile women. Therefore, infertile 
and obese patients may benefit if their serum progranulin levels decrease. Further studies are needed to elucidate this issue. (Endokrynol 
Pol 2018; 69 (6): 661–666)
Keywords: progranulin; granulin; obesity; infertility
Streszczenie
Wstęp: Celem badania była analiza zmian stężeń progranuliny i hormonów płciowych u bezpłodnych kobiet z otyłością. 
Materiał i metody: Do przekrojowego badania włączono 171 bezpłodnych kobiet, które chciały zajść w ciążę. Ocena wstępna obejmowała 
pomiary masy ciała, wzrostu, obwodu talii i bioder w celu obliczenia wskaźnika masy ciała (BMI) i współczynnika talia/biodra. Wszystkie 
uczestniczki podzielono na dwie grupy w zależności od wartości BMI, tworząc grupę kontrolną (< 30 kg/m2, n = 135) oraz grupę badaną 
(≥ 30 kg/m2, n = 36). Po wykonaniu pomiarów antropometrycznych od wszystkich kobiet pobrano próbki krwi żylnej do oznaczeń stę-
żeń estradiolu i hormonu folikulotropowego (FSH), hormonu luteinizującego, testosteronu całkowitego (TT), 17-hydroksyprogesteronu, 
siarczanu dehydroepiandrosteronu, hormonu antymüllerowskiego i progranuliny.
Wyniki: W badaniu wykazano, że u otyłych kobiet stężenie FSH jest podwyższone (p < 0,01). W tej grupie kobiet stwierdzono również 
podwyższone stężenie TT (p < 0,05). Stężenie progranuliny było wyższe w grupie badanej niż w grupie kontrolnej (p < 0,05). W analizie 
regresji wykazano zależność między stężeniem progranuliny w surowicy a BMI (p < 0,05). 
Wnioski: Uzyskane wyniki potwierdzają, że u bezpłodnych kobiet podwyższone stężenie progranuliny wiąże się z otyłością. Dlatego 
obniżenie stężenia progranuliny w surowicy może przynieść korzystne efekty u kobiet z bezpłodnością i otyłością. Potrzebne są dalsze 
badania w tej dziedzinie. (Endokrynol Pol 2018; 69 (6): 661–666)
Słowa kluczowe: progranulina; granulina; otyłość; bezpłodność
Introduction
Progranulin is also known as proepithelin, or plasma 
cell derived growth factor and a precursor of granulin 
for proteolytic cleavage process. It was originally dis-
covered as an acrosomal glycoprotein, and named as 
acrogranin, which was found to be synthesised dur-
ing spermatogenesis of guinea pigs [1]. It has some 
growth factor-like properties, and it is involved in early 
embryogenesis [2], wound repair, and tissue remodel-
ling [3]. It has the properties of a pluripotent growth 
factor mediating wound healing, tumorigenesis, and 
progression of cell cycle [4]. It has also been suggested 
that it plays a role in various disorders including breast, 
ovarian, cervical, gastrointestinal, and kidney cancers 
[5–9] as well as neurodegenerative disorders including 
frontotemporal dementia [10] and rheumatoid arthritis 
[11]. Progranulin is protein produced in response to 
hypoxia or acidosis [12]. It has complex physiological 
and pathological functions because it has both anti- 
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The initial assessments of the patients included the 
measurements of weight, height, waist circumference 
(WC), and hip circumference (HC) to calculate BMI 
and waist/hip ratio (WHR). BMI was calculated as 
weight (kg)/height2 (m2). All participants were catego-
rised into two groups in accordance with their BMI, 
as a control group (< 30 kg/m2, n = 135) and a study 
group (≥ 30 kg/m2, n = 36). WC was measured at the 
mid-point of the lowest margin of 12th rib and the lateral 
iliac crest during normal expiration. HC was measured 
at the maximum extension of the major trochanters. All 
anthropometric measurements were performed with 
the same scale, and by the same observer.
Data collection and assays
Venous blood samples of the participants were obtained 
from their antecubital veins between 08:00 and 10:00 
after an eight-hour fasting period on menstrual days 
2–5 for oestradiol (E2), follicle stimulating hormone 
(FSH), luteinising hormone (LH), total testosterone 
(TT), 17-Hydroxyprogesterone (17OHP), dehydro-
epiandrosterone sulphate (DHEAS), anti-Müllerian 
hormone (AMH), and progranulin measurements. The 
samples were allowed to clot completely at room tem-
perature, and then they were centrifuged within 30 min 
at 3000 rpm for 20 minutes. The serums for AMH and 
progranulin measurements were frozen at –80°C within 
two hours, until they were analysed. The serums were 
analysed on a daily basis for E2, FSH, LH, TT, 17OHP, and 
DHEAS using electrochemiluminescence immunoassay 
(ECLIA) method and an auto-analyser (Cobas 6000, E 
601 Roche Diagnostics, GmbH, Mannheim, Germany). 
The AMH samples were measured with the ECLIA 
method using an auto-analyser (Cobas 6000, 601 Roche 
Diagnostics, GmbH, Mannheim, Germany). 
The serum progranulin levels were determined 
using commercially available enzyme-linked immuno-
sorbent assay (ELISA) kit developed for PGRN (Biotek 
Synergy HT, Cloud-Clone Corp., Houston, USA) and 
given as ng/mL. CVs for intra-assay were < 10%, CVs 
for inter assay were < 12%, sensitivity was 0.05 ng/mL, 
and assay range was 1.56–100 ng/mL.
Statistical analysis
All data analyses were performed using SPSS (Statistical 
Packages for The Social Sciences) software, version 21 (SPSS 
Inc., Chicago, USA). The Kolmogorov-Smirnov and 
Shapiro-Wilk tests were used to test normality of dis-
tribution. Continuous parameters were presented as 
mean ± standard deviation (SD). Continuous variables 
were compared using independent samples t-test due 
to normally distributed data. Pearson or Spearman 
correlation analysis, where appropriate, was used to 
test whether progranulin showed any significant linear 
and pro-inflammatory characteristics [13, 14]. The 
data suggest that the full-length form of progranulin 
exerts trophic and anti-inflammatory actions. However, 
proteolytic cleavage of progranulin produces granulin 
peptides that induce inflammatory action [15]. 
Recently, obesity has been increasing worldwide 
as an epidemic. It has been associated with a chronic 
low-grade inflammatory state, which is character-
ised by increased pro-inflammatory and decreased 
anti-inflammatory factors. More than one third of the 
adult population is obese in Turkey, similarly to most 
of the world [16, 17]. The World Health Organisation 
has defined obesity as body mass index (BMI) equal to 
or greater than 30 kg/m2 [18].
Obese women are more susceptible to anovulation 
and abnormal uterine bleeding, infertility, miscarriage, 
as well as antenatal and neonatal complications in 
which the mechanism is complex and multifactorial 
[19]. Obese women also show impaired development 
of ovarian follicles and oocytes, and abnormal fertilisa-
tion, embryo development, and implantation [20, 21]. 
Therefore, progranulin found in adipose tissue may 
participate in chronic inflammation associated with 
obesity. To our knowledge, only scarce studies in the lit-
erature have investigated the role of progranulin on the 
pathogenesis of obesity and infertility. Thus, we aimed 
to investigate whether there were serum progranulin 
changes and any correlations between progranulin and 
sex hormones in obese infertile women.
Material and methods
Study population and design
All of the 171 women admitted to the Reproductive En-
docrinology Department of Hitit University Hospital for 
fertility desire in Corum, Turkey between January 1 and 
September 30 2016 were included in this cross-sectional 
study. The study protocol was approved by the Insti-
tutional Review Board of Ankara Numune Education 
and Research Hospital (reference number: E–15–563), 
in accordance with the Declaration of Helsinki, 2013 
Brazil version. Written, informed consent was obtained 
from each participant before starting the study. The 
exclusion criteria were accepted as history of pelvic 
surgery, chemotherapy and/or radiotherapy, ovarian 
masses, polycystic ovarian syndrome, endometriosis, 
severe systemic diseases including diabetes mellitus, 
cardiovascular, renal, hepatic, autoimmune or endocrine 
disorders, use of drugs likely to affect ovarian functions, 
smoking or alcohol consumption, and pregnancy or lac-
tation. Infertility was described as the failure to conceive 
in one year with regular sexual activity. The participant 
women who had a diagnosis of unexplained infertility 
were included in the present study.
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relationship with other study parameters. Multiple 
linear regression analysis was used to investigate the 
associations between progranulin and the other study 
parameters. A p value less than 0.05 was considered as 
statistically significant. 
Results
The comparisons of anthropometric and biochemical 
parameters among the overweight and obese women 
in relation with BMI are demonstrated in Table I. No sig-
nificant difference in mean age was observed between 
the control and study groups (p > 0.05). As expected, the 
anthropometric measurements including BMI, WC, and 
HC were higher in the study group (p < 0.001). How-
ever, the mean WHR did not differ between the two 
groups (p > 0.05). Serum E2, LH, 17OHP, and DHEAS 
levels were similar in the control and study groups 
(p > 0.05). The non-obese women had higher FSH levels 
compared to obese women (p < 0.01). Elevated TT levels 
were detected in obese women (p < 0.05). Moreover, the 
comparisons of circulating AMH levels did not confirm 
any difference between the two groups (p > 0.05). The 
comparisons revealed increased progranulin concentra-
tions in the study group (p < 0.05). 
Correlation analysis showed that the BMI (r = 0.228, 
p = 0.003), WC (r = 0.171, p = 0.018), and HC (r = 0.172, 
p = 0.025) correlated with the levels of progranulin 
(Table II). 
Multiple linear regression analysis revealed that 
there was a relationship between the serum progranu-
lin concentrations and BMI. In another words, it was 
observed that the BMI could be a variable affecting 
progranulin levels, and the other variables could have 
no effect on progranulin levels, as shown in Table III 
(p < 0.05). 
Discussion
In this study, we investigated the relationship be-
tween serum progranulin levels and obesity in infer-
tile women and found that serum progranulin levels 
were significantly higher in obese infertile women 
when compared to overweight infertile women. 
Only scarce clinical studies demonstrated positive 
correlations between circulating progranulin levels 
and components of metabolic syndrome, including 
insulin resistance (IR), dyslipidaemia, and obesity. 
High progranulin levels have been reported in obesity 
[22]. Both animal [23] and human studies [24, 25] have 
reported a relationship between progranulin levels 
and adiposity. 
It was also demonstrated that serum progranulin 
was associated with parameters of adiposity, IR, and 
Table I. Anthropometric and biochemical characteristics 
among the overweight and obese women according to 
BMI
Tabela I. Parametry antropometryczne i biochemiczne kobiet 
z otyłością i nadwagą w zależności od wartości wskaźnika 
BMI
Parameters Control group 
(n = 135)
Study group 
(n = 36)
p 
Age (year) 30.2 ± 5.9 30.4 ± 6.2 0.812
BMI [kg/m2] 24.2 ± 3.0 33.7 ± 3.3 < 0.001*
WC [cm] 86.8 ± 11.0 101.4 ± 12.9 < 0.001*
HC [cm] 102.0 ± 8.2 116.8 ± 7.6 < 0.001*
WHR 0.9 ± 0.1 0.9 ± 0.1 0.190
E2 [pg/mL] 45.4 ± 24.2 43.8 ± 41.8 0.676
FSH [IU/L] 7.4 ± 2.4 6.3 ± 1.5 0.006*
LH [IU/L] 6.7 ± 2.8 6.1 ± 3.3 0.237
TT [ng/dL] 24.1 ± 13.5 33.4 ± 41.1 0.027*
17OHP [ng/dL] 141.0 ± 46.0 76.0 ± 45.1 0.399
DHEAS [mcg/dL] 221.7 ± 100.0 213.4 ± 92.4 0.656
AMH [ng/dL] 4.2 ± 3.8 4.3 ± 4.1 0.936
Progranulin [ng/mL] 2.7 ± 1.1 3.2 ± 1.1 0.019*
*statistically significant
BMI — body mass index; WC — waist circumference; HC — hip 
circumference; WHR — waist–hip ratio; E2 — oestradiol; FSH — follicle 
stimulating hormone; LH — luteinizing hormone; TT — total testosterone; 
17OHP — 17-hydroxyprogesterone; DHEAS — dehydroepiandrosterone 
sulphate; AMH — anti-Müllerian hormone 
Table II. Correlations between serum progranulin and other 
parameters
Tabela II. Korelacje między stężeniem progranuliny 
w surowicy a innymi parametrami
r p
Age (year) 0.074 0.335
BMI [kg/m2] 0.228 0.003*
WC [cm] 0.171 0.018*
HC [cm] 0.172 0.025*
WHR 0.130 0.089
E2 [pg/mL] 0.045 0.558
FSH [IU/L] 0.081 0.292
LH [IU/L] –0.079 0.303
TT [ng/dL] 0.031 0.689
17OHP [ng/dL] 0.017 0.822
DHEAS [mcg/dL] –0.052 0.497
AMH [ng/dL] –0.094 0.219
*statistically significant
BMI — body mass index; WC — waist circumference; HC — hip 
circumference; WHR — waist–hip ratio; E2 — oestradiol; FSH — follicle 
stimulating hormone; LH — luteinizing hormone; TT — total testosterone; 
17OHP — 17-hydroxyprogesterone; DHEAS — dehydroepiandrosterone 
sulphate; AMH — anti-Müllerian hormone 
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several inflammatory factors [24]. Progranulin is par-
ticularly more highly expressed in visceral adipose 
tissues of morbid-obese, insulin-resistant patients [22, 
26]. In a research from Brazil, the authors demonstrated 
that progranulin may be involved in the pathogenesis 
of obesity and become a target for metabolic disorder 
prevention or treatment [27]. When taken altogether, 
this evidence supports that progranulin plays a regu-
latory role in glucose and energy homeostasis, and it 
is possible that it may contribute to the progression of 
metabolic syndrome [28]. 
Qu et al. reported higher interleukin 6 (IL-6) levels 
in obese patients, and high IL-6 levels were associated 
with increased circulating progranulin levels [24]. Posi-
tive correlations of progranulin with C-reactive protein 
and IL-6 were also reported in human studies [22, 24]. 
In another study, progranulin seemed to play a role 
on this process, by recruiting monocytes into adipose 
tissue as well as monocyte chemoattractant protein-1, 
due to its characteristic activity [29].
It was suggested that progranulin could be involved 
in the growth of adipose tissue [30]. It has been known 
that angiogenesis follows expansion of fat mass in 
obesity [31]. In fact, progranulin has previously been 
linked to formation of vessels [32]. However, the role 
of progranulin in adipogenesis is not yet clear. More-
over, progranulin shows an anorexigenic effect in the 
lean state, but a resistance is observed, and this leads 
to increased food intake [33]. Although progranulin 
shows an anti-inflammatory effect in acute conditions 
of ischaemia-perfusion injury [34, 35], it is associated 
with IR and inflammation in obesity, as a chronic con-
dition [23]. 
Jian et al. published a review about the role of 
progranulin in inflammation. They also mentioned 
the proinflammatory effect of progranulin in chronic 
inflammatory conditions such as obesity. They con-
cluded with insights into the immunomodulating, 
anti-inflammatory, therapeutic potential of progranulin 
in treating diseases with an inflammatory aetiology 
[36]. In a review by Fasshauer et al., secretion of adipo-
kines like progranulin were altered in adipose tissue 
dysfunction, and they may contribute to a spectrum 
of obesity-associated diseases. The authors also stated 
that adipokines are promising candidates both for novel 
pharmacological treatment strategies and as diagnostic 
tools [37]. 
There is evidence that the administration of pro-
granulin in the mice hypothalamus significantly sup-
presses fasting-induced feeding and body weight gain 
in a dose-dependent manner. However, in obesity, 
a resistance to the anorexigenic effects of progranulin 
may contribute to increased food intake [33].
Our study harbours some limitations that must 
be mentioned. Firstly, the sample size is small, and 
the non-significant associations between progranu-
lin and some factors could have become statistically 
significant if larger samples were studied. Secondly, 
Table III. Outcomes of multiple linear regression analysis — progranulin level increases proportionally with BMI
Tabela III. Wyniki analizy liniowej regresji wielokrotnej — stężenie progranuliny podwyższa się proporcjonalnie do wartości BMI
Parameters Coefficient Standard Error 95% Confidence Interval p 
Lower Bound Upper Bound
(Constant) 0.123 1.288 –2.415 2.661 0.924
Age [year] –0.004 0.016 –0.036 0.029 0.829
BMI [kg/m2] 0.050 0.030 0.011 0.088 0.011*
WC [cm] –0.114 0.095 –0.301 0.072 0.231
HC [cm] 0.091 0.081 –0.066 0.250 0.258
WHR 1.149 1.223 –1.301 3.493 0.349
E2 [pg/mL] 0.002 0.003 –0.004 0.008 0.507
FSH [IU/L] 0.071 0.043 –0.04 0.156 0.100
LH [IU/L] –0.009 0.035 –0.077 0.059 0.799
TT [ng/dL] 0.001 0.004 –0.007 0.010 0.723
17OHP [ng/dL] 0.007 0.021 –0.035 0.049 0.745
DHEAS [mcg/dL] –0001 0.001 –0.003 0.001 0.585
AMH [ng/dL] 0.002 0.027 –0.052 0.055 0.945
*statistically significant
BMI — body mass index; WC — waist circumference; HC — hip circumference; WHR — waist–hip ratio; E2 — oestradiol; FSH — follicle stimulating hormone; 
LH — luteinizing hormone; TT — total testosterone; 17OHP — 17-hydroxyprogesterone; DHEAS — dehydroepiandrosterone sulphate; AMH — anti-Müllerian hormone 
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our study is cross-sectional, and therefore causality of 
progranulin and other mediators such as IL-6 cannot 
be established.
Conclusions
Our results suggest that elevated progranulin 
serum levels are associated with obesity. Because 
progranulin is a key adipokine that mediates obesity 
through pro-inflammatory adipokines, infertile and 
obese patients may benefit if their serum progranulin 
levels decrease. Further prospective investigations are 
merited to illuminate the role of progranulin on the 
pathogenesis of obesity. 
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